Dairy industry economics and milk prices - directly impacts demand for rumen-protected nutrients as dairy farmers adjust feed formulations based on profitability
New product launches and regulatory approvals in human nutrition (particularly infant formula ingredients and novel encapsulated nutrients for functional foods)
Raw material cost inflation for choline chloride, methionine, and coating materials - margin compression risk when input costs rise faster than pricing adjustments
M&A activity and bolt-on acquisitions in specialty nutrition markets - company has history of strategic purchases to expand product portfolio
moderate - Animal nutrition demand correlates with livestock commodity prices and farm income, which fluctuate with agricultural cycles and global protein demand. Human nutrition shows more resilience as dietary supplement consumption and infant formula demand remain relatively stable through economic cycles. Industrial specialty products segment has higher cyclicality tied to manufacturing activity and construction markets. Overall revenue mix provides partial insulation from severe economic downturns, though margin pressure can emerge if input costs remain elevated while end-market pricing weakens.
Rising interest rates have modest negative impact through higher borrowing costs on the company's debt (though leverage is low at 0.13x D/E), and valuation multiple compression as investors rotate from growth-oriented specialty chemical stocks to higher-yielding alternatives. Rate increases can also pressure agricultural borrowing costs, potentially reducing dairy farmer willingness to invest in premium feed additives. However, the company's strong cash generation and minimal refinancing risk limit direct financial statement impact.
Regulatory changes in dietary supplement and food fortification markets - FDA or EU restrictions on specific ingredients could eliminate product lines or require costly reformulations
Shift toward plant-based proteins and alternative dairy products - long-term decline in conventional dairy farming would reduce addressable market for rumen-protected nutrients
Consolidation among food and supplement manufacturers - larger customers gain negotiating leverage and may demand price concessions or backward integrate into ingredient production
growth - The stock attracts investors seeking exposure to secular growth in nutritional ingredients and specialty chemicals with limited commodity exposure. The company's consistent margin expansion, new product pipeline, and M&A-driven growth strategy appeal to investors willing to pay premium valuations (22.5x EV/EBITDA) for differentiated specialty chemical businesses. Recent 17.5% EPS growth and strong ROA (22%) demonstrate quality characteristics. Lower volatility versus broad chemicals sector due to niche market positions and recurring revenue from formulation lock-in.
Trend
-5.8% vs SMA 50 · -1.6% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2024 | $953.6M $946.9M–$960.4M | — | $3.98 | — | ±3% | Low2 |
FY2025 | $1.0B $1.0B–$1.0B | ▲ +8.3% | $4.71 | ▲ +18.4% | ±0% | Moderate3 |
FY2026(current) | $1.1B $1.1B–$1.1B | ▲ +7.1% | $5.24 | ▲ +11.1% | ±3% | Moderate3 |
Dividend per payment — last 8 periods
INSTITUTIONAL OWNERSHIP
BCPC News
About
founded in 1967, balchem provides state-of-the-art solutions and the finest quality products for a range of industries worldwide. our company consists of four business segments: human nutrition & health; specialty products; animal nutrition and health and industrial products. balchem employs approximately 1,000 people worldwide who are engaged in many diverse activities, developing our company into chosen market leadership positions. visit our website at www.balchem.com to learn more about us and the exciting opportunities we have available!
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
BCPC◀ | $159.02 | -1.28% | $5.1B | 32.5 | +875.3% | 1493.0% | 1500 |
| $506.11 | -1.08% | $234.1B | 33.0 | +297.2% | 2029.7% | 1506 | |
| $109.06 | -6.25% | $116.4B | 14.0 | +1907.6% | 3206.3% | 1507 | |
| $63.01 | -4.73% | $90.6B | 33.3 | +112.4% | 856.2% | 1516 | |
| $300.10 | -2.94% | $74.0B | 28.4 | +206.0% | 1089.5% | 1477 | |
| $247.62 | -0.51% | $69.7B | 33.2 | +215.9% | 1290.7% | 1473 | |
| $295.38 | -1.50% | $65.8B | 31.2 | -52.3% | -327.7% | 1502 | |
| Sector avg | — | -2.61% | — | 29.4 | +508.9% | 1376.8% | 1497 |